Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Investigator: Eric Bernicker, MD

Study Coordinator: Lacey Burey

Status: Enrolling

ClinicalTrials.gov Number: NCT03539536

Phone: 713.441.1159

Protocol Number: Pro00022533

Description

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
More to Explore
Live Chat Available